Advances in understanding myeloma biology have shown that disease progression is not only the consequence of intrinsic tumor changes but also of interactions between the tumor and the microenvironment in which the cancer grows. The immune system is an important component of the tumor microenvironment in myeloma, and acting on the immune system is an appealing new treatment strategy. There are 2 ways to act toward immune cells and boost antitumor immunity: (1) to increase antitumor activity (acting on T and NK cytotoxic cells), and (2) to reduce immunosuppression (acting on myeloid-derived stem cells and T regulatory cells). Checkpoint inhibitors and adoptive cell therapy (ACT) are 2 of the main actors, together with monoclonal antibodies and immunomodulatory agents, in the immune-oncologic approach. The aim of checkpoint inhibitors is to release the brakes that block the action of the immune system against the tumor. Anti-programmed death-1 (PD-1) and PD-1-Ligand, as well as anti-CTLA4 and KIR are currently under evaluation, as single agents or in combination, with the best results achieved so far with combination of antiePD-1 and immunomodulatory agents. The aim of ACT is to create an immune effector specific against the tumor. Preliminary results on chimeric antigen receptor (CAR) T cells, first against CD19, and more recently against B-cell maturation antigen, have shown to induce durable responses in heavily pretreated patients. This review focuses on the most recent clinical results available on the use of checkpoint inhibitors and CAR-T cells in myeloma, in the context of the new immune-oncologic approach.
Introduction
There have been significant advances in the understanding of the biology of multiple myeloma (MM) in recent years. In the classic view of the pathogenesis of MM, an initiating hit is necessary to immortalize a myeloma-propagating cell. This cell then acquires additional genetic hits over time, mediated by translocation, loss of heterozygosity, gene amplification, mutation, or epigenetic changes, which further deregulate the behavior of the MM-propagating cell, leading step by step to the well-known MM features. 1 Many of the genes and pathways mediating this transformation process have now been characterized. Nevertheless, disease progression is not only the consequence of intrinsic tumor changes. Interactions between the tumor and the microenvironment in which the cancer grows play an essential role, 2 and the focus of studies has shifted from the disease itself alone to the disease in the context of the microenvironment in which the tumor grows. The immune system is an important component of the tumor microenvironment in MM, as well as in many other cancers, and is the focus of the immune-oncology approach.
secrete inflammatory cytokines, and present tumor cellederived molecules to T and B cells. Activation of T and B cells leads to the expansion of tumor-specific cell clones and antibodies. Moreover, adaptive immunity subsets produce additional cytokines that further promote activation of innate immunity. The final goal of the adaptive immune system is to the eliminate the remaining tumor cells and to generate immune memory against specific tumor components, thus preventing tumor recurrence. 6 This process can result in different outcomes. A highly immunogenic tumor in a highly immunocompetent individual can eliminate the arising tumor. In a less immunocompetent individual and/or in case of a less immunogenic tumor, there can be an incomplete elimination leading to the survival of some cancer cells that nevertheless remain under immunosurveillance. This phase could be at some point disturbed by changes in the tumor that allow it to avoid immunosurveillance, or changes in the immune system that weaken its capacity to keep the tumor under control, leading to tumor escape. 7 The escape phase of immunosurveillance is characterized by an increase in immunosuppressive cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Immunosuppressive cytokines derived from Tregs, MDSCs, and tumor cells themselves can hamper the effector function of T cells. [8] [9] [10] MM is characterized by a profound immune dysfunction affecting both the innate and adaptive immune system. 11 Antigen cross-presentation is the dominant mechanism of tumor antigen priming 12 play an important role in maintaining immunosuppression. As an example, they can produce TGFb and express programmed cell death ligand (PDL)-1, both leading to T-cell inhibition. Taken together, all these mechanisms suggest a complex interaction between MM cells and the immune system, with several possible targets for the immune-oncologic approach.
Immune-oncologic Approach in MM
Immune therapy can be directed against the tumor itself or toward immune cells. There are 2 strategies to act toward immune cells and boost antitumor immunity: one consists of increasing antitumor activity (acting on T and NK cytotoxic cells), the other in reducing immunosuppression (acting on MDSCs and Tregs). Treatment approaches include monoclonal antibodies (mAbs) targeting surface molecules present on MM cells, mAbs targeting checkpoint inhibitors on immune cells/tumor cells, immunomodulation, vaccines, and adoptive cell therapy (ACT). Several targets, however, are expressed on both MM cells and immune cells, thus leading to complex mechanism of actions.
This review focuses on checkpoint inhibitors and chimeric antigen receptor (CAR) T-cellebased ACT (Figure 1 ). To contextualize the role of checkpoint inhibitors and ACT in the immune-oncology approach, we provide a brief summary of the main mechanisms by which mAbs target surface molecules present on the MM cells, and immunomodulation and vaccines act on the immune system.
Elotuzumab is a mAb targeting SLAMF7 (also known as CS-1), present on both MM cells and NK cells. It causes MM cell death via a dual mechanism of action. The Fab portion of elotuzumab binds SLAM F7 on MM cells, and the Fc portion binds CD16 on NK. This interaction triggers NK activation, release of cytotoxic granules, and MM cell killing. 17, 18 This agent did not show efficacy as a single agent, but proved to be effective in combination with both lenalidomide and bortezomib. 19, 20 Daratumumab is a human immunoglobulin (Ig)G1 mAb that targets CD38-expressing cells. Daratumumab binding to CD38 induces tumor cell death through direct and indirect mechanisms. It can induce apoptosis via CD38 cross-linking and has an antitumor effect mediated by the activation of complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and antibodydependent cell cytotoxicity. CD38 is also expressed on highly immunosuppressive Treg and Breg cells, as well as on MDSCs; daratumumab eliminates these highly immunosuppressive cells, thus stimulating cytotoxic T-cellemediated antitumor effects. [21] [22] [23] [24] [25] Daratumumab showed efficacy as a single agent in heavily pretreated patients, 26, 27 as well as in combination with bortezomib and with lenalidomide. 28, 29 Immunomodulatory drugs are of particular interest in combination with both mAbs and checkpoint inhibitors. In particular, lenalidomide enhances immunogenicity by inducing T-cell activation through increased tyrosine kinase activity of the CD28 receptor, downregulation of CD45RA on T cells, and downregulation of SOCS1 on stromal cells in the microenvironment. [30] [31] [32] The aim of vaccines is to increase the frequency of antigen-specific T cells or antibodies. Vaccination approaches in MM include idiotype vaccines, dendritic cellebased and granulocyte-macrophage colonystimulating factorebased vaccines and cancer testis antigens vaccines. Nevertheless, the main limitation to the efficacy of this approach is the intrinsic immune dysfunction associated with the tumor itself, especially in the presence of high disease burden, and the use in a therapeutic setting and not prevention setting as for antipathogen vaccines. 33 
Checkpoint Blockade Therapy
Inhibitory molecules known as "immune checkpoint proteins" are expressed by a variety of immune cells (eg, T and NK cells) to control the intensity and duration of immune responses, playing a pivotal role in the induction of peripheral self-tolerance and the limitation of tissue damage. 34 The avoidance of immune-mediated destruction is a well-known hallmark of cancer biology, 35 Immuno-oncologic Approaches in Myeloma CTLA-4. CTLA-4 was the first immune checkpoint molecule fulfilling the requirements to be clinically targeted in cancer. 40 CTLA-4 is a fundamental negative regulator of T-cell function, and its absence causes immune hyperactivation and lethal diffuse lymphocytic infiltration in mice models. 41 In T cells, CTLA-4
antagonizes the activating signal mediated by CD28, competing for the same ligand (B7-1) expressed by dendritic cells. 42 On the binding of B7-1, CTLA-4 induces antigen-specific anergy in T cells. 43 In patients with MM, CTLA-4 is significantly overexpressed on CD4 þ and CD8 þ T cells in the bone marrow but not in the peripheral blood, compared with healthy donors. 2 This evidence suggests an enhanced T-cell unresponsiveness toward MM cells, especially at the tumor site, that can be theoretically reverted by CTLA-4 inhibition. Building on this hypothesis and on the clinical success of CTLA-4 inhibition in patients with melanoma, 40 2 mAbs targeting CTLA-4 are in clinical development in MM. Ipilimumab (IgG1, fully human) has been studied as a single agent in 29 hematologic patients (21% with MM) relapsing from allogeneic stem cell transplantation (SCT) to stimulate the graftversus-tumor effect mediated by effector T cells in this setting, 36 but no objective responses were elicited in patients with MM. Due to the peculiar mechanism of action, the major risk associated with checkpoint blockade therapy is to induce autoimmune-like syndromes, known as immune-related adverse events (IRAEs). This aspect is very relevant in the allogeneic setting, with an additional risk of graft-versus-host disease (GvHD). In this trial, ipilimumab did not induce grade 3-4 GvHD or graft rejection. IRAEs were registered in 4 patients (1 grade 3 polyarthritis, 1 grade 2 hyperthyroidism, 1 recurrent grade 4 pneumonitis, and 1 obstructive defect with no infectious cause identified); however, none of them had MM.
Trials in patients with MM are currently evaluating ipilimumabbased combinations (NCT01592370), comparing ipilimumab with another checkpoint inhibitor acting on a different target (nivolumab) in the allogeneic SCT setting (NCT01822509) and combining ipilimumab with nivolumab in the autologous SCT setting (NCT02681302).
Tremelimumab (IgG2, fully human) is another CTLA-4 targeting mAb. Although no clinical data are yet available in patients with MM, a trial involving tremelimumab-combination therapy with another checkpoint inhibitor acting toward a different target (durvalumumab) after autologous SCT is currently planned (NCT02716805).
PD-1/PDL-1. The immune checkpoint pathway that produced the most promising preclinical and clinical data in MM is based on the interaction between 2 transmembrane proteins: PD-1 and PDL-1. 44 PD-1, differently from CTLA-4, is expressed not only by T cells, but also by NK cells, B cells, and other immune cell subsets, playing a pivotal role in the balance between immune system activation and self-tolerance. 45 Differently from CTLA-4, PD1edeficient mice develop lupus-like systemic inflammation, 46 suggesting that CTLA-4 and PD-1/PDL-1 axis may work in slightly different aspects of immune regulation. Table 2 summarizes the main similarities and differences in CTLA-4 and PD-1. PD-1 may bind another ligand besides PDL-1, known as PDL-2. PDL-2 expression could be detected in the microenvironment of solid tumors; however, it does not seem to be a key inhibitor of Tcell function at the tumor site. 52 There is evidence that blocking PD-1 and/or PDL-1 through mAbs to prevent their interaction can enhance myeloma-cell killing by T and NK cells in vitro. 53 Moreover, in an MM mouse model,
Hallett and colleagues 51 demonstrated that PDL-1 on MM cells engaging PD-1 expressed by T cells and NK cells, decrease their cytotoxic function, proliferation, and cytokine production, thus leading to a functionally exhausted state of these cells. Based on these biologic data and on the success of mAbs targeting PD-1 in solid tumors 54 and Hodgkin lymphoma, 55 several mAbs targeting this pathway are being evaluated in MM. Nivolumab is a fully human IgGk mAb targeting PD-1. A phase Ib trial evaluated its safety and efficacy as a single agent in hematologic patients affected by several malignancies, among whom were 27 patients with relapsed and/or refractory MM (RRMM). Unfortunately, in this subgroup of patients, no objective responses were reported. 37 Building on pharmacokinetic data demonstrating a long-lasting binding of nivolumab to its receptor, Funt and colleagues 56 recently reported on the next line of therapy after nivolumab infusion in 8 patients with RRMM. An unusually low rate of progressive disease was reported in this highly refractory patient population and, interestingly, a patient who relapsed with an isolated plasmacytoma received only radiotherapy and then resumed nivolumab treatment with a progression-free period of more than 2 years. Several ongoing trials are evaluating nivolumab in combination with daratumumab AE pomalidomide-dexamethasone (NCT01592370), pomalidomide-dexamethasone AE elotuzumab (NCT02726581), and with anti-CTLA4 mAbs after autologous (NCT02681302) and allogeneic (NCT01822509) SCT. Pembrolizumab is a humanized antiePD-1 IgGk mAb. It is probably the antiePD-1 mAb evaluated in the greatest number of malignancy types. Data on monotherapy in the MM field are lacking; however, pembrolizumab has been tested in combination with dexamethasone and immunomodulatory agents in patients with RRMM. A phase I study in 40 patients with RRMM failing at least 2 previous therapeutic lines evaluated safety and efficacy of pembrolizumab added to lenalidomide-dexamethasone backbone treatment. 38 The maximally tolerated dose for pembrolizumab was 200 mg every 21 days and the overall response rate (ORR) was 50%. Of note, responses were also elicited in lenalidomiderefractory patients, suggesting that pembrolizumab and lenalidomide could act synergically also in patients refractory to immunomodulators alone. Safety profile was acceptable, and hematologic toxicities (thrombocytopenia 41%, neutropenia 37%) were the most common treatment-related adverse events. Of note, IRAEs were rare, and the most frequent nonhematologic toxicity was mild diarrhea (28%, all cases grade 2). A phase III randomized trial evaluating first-line treatment with lenalidomidedexamethasone AE pembrolizumab in transplant-ineligible patients with MM (NCT02579863) is currently ongoing.
A phase II trial in 48 patients with lenalidomide-refractory RRMM evaluated pembrolizumab in combination with pomalidomide and dexamethasone. 39 Besides lenalidomide, 80% of enrolled patients were also refractory to a proteasome inhibitor. The ORR was 56% and responding patients had a median duration of response of more than 6 months. Interestingly, double-refractory patients had a superimposable ORR (55%). IRAEs reported in this trial were interstitial pneumonitis (13%), hypothyroidism (10%), hepatic cytolysis (6%), adrenal insufficiency (4%), and vitiligo (2%). Additional data will come from a phase III trial that is currently enrolling patients with RRMM that will evaluate pomalidomidedexamethasone AE pembrolizumab (NCT02576977 Based on this rationale, IPH2101, a human IgG4 mAb targeting KIR2D receptors, has been evaluated in patients with MM. In a phase I trial, 32 patients with RRMM treated with IPH2101 monotherapy did not show any objective responses; however, safety was very good with no dose-limiting toxicities. 59 The lack of singleagent activity was confirmed also in the smoldering MM setting by a phase II trial. 62 A phase I trial evaluated the combination of IPH2101 with lenalidomide in patients with RRMM. 63 Safety profile was acceptable and objective responses were reported in 5 of 15 enrolled patients. Nevertheless, the small number of patients and the exclusion of lenalidomide-refractory patients make it difficult to draw conclusions on the efficacy of IPH2101 in the context of immunomodulatory pretreated patients. Another mAb targeting KIRs (lirilumab) is under development. Combination study with elotuzumab (NCT02252263) and nivolumab (NCT01592370) are currently ongoing.
CAR-Tebased ACT
CAR-T cells are autologous or allogeneic T cells genetically engineered to express a chimeric antigen receptor specific for a tumor-associated antigen expressed on the neoplastic cell surface. CARs are also "equipped" with costimulatory domains, which enhance activation and function of CAR-T cells, and promote their proliferation and cytokine release. 64 CAR-T cells have both advantages and limitations. They are not restricted by patient HLA. However, selecting appropriate antigens is crucial to prevent ontarget off-tumor toxicity. Many potential targets have a broad expression on normal cells and tissues. 65 Major clinical trials have so far used CAR-T cells that greatly differed in both targeted antigens and costimulatory domains. CAR-T cells directed against CD19 initially showed a dramatic potential in acute lymphoblastic leukemia and chronic lymphocytic leukemia. [66] [67] [68] Even though CD19 expression is not usually associated with MM and it is not considered a therapeutic target, 69 some studies identified its expression on a putative minor MM stem cell subset 70 that may partly be responsible for disease recurrence. Despite being hotly debated, the potential existence of a CD19 þ MM stem cell formed the rationale for conducting clinical trials with specific CAR against CD19. 71 Garfall et al 71 initially described 1 patient treated with anti-CD19 CAR-T cells (CTL019). The patient underwent CTL019 infusion after a standard autograft. Following cell infusion, no fever or other signs of cytokine release syndrome (CRS) were noted and, importantly, CTL019 cells were detected in both blood and bone marrow for up to several days after the infusion. The patient started lenalidomide maintenance 3 months later. Complete response (CR) was still observed at 1 year of follow-up. It is remarkable that the response was achieved despite the absence of CD19 expression on 99.95% of plasma cells. An update of this clinical trial on a series of 12 patients was reported at American Society of Hematology (ASH) meeting in December 2016. 72 Overall, 10 of 12 patients enrolled were infused with CTL019 12 to 14 days after high-dose melphalan and an autograft. Six patients showed very good partial response (VGPR), 2 partial response (PR), 2 progressive disease (PD). Of note, only minor adverse effects were reported. More recently, the B-cell maturation antigen (BCMA) has drawn increasing attention as a CAR target in MM. BCMA is a cell surface protein involved in the differentiation and maturation of B cells into plasma cells; however, BCMA is highly expressed also on MM cells. Ali et al 73 reported on a phase I study with an anti-BCMA-CAR with a CD28 costimulatory molecule. Twelve patients received escalating doses of CAR-T cells at 0.3, 1, 3, or 9 Â 10 6 /kg. All patients were immune-suppressed with cyclophosphamide and fludarabine before CAR-T cell infusions. Responses included stringent CR (n ¼ 1), VGPR (n ¼ 2), PR (n ¼ 1), and PD (n ¼ 8). Both best responses and side effects occurred in the highest-dose patients. Only 1 patient has so far been reported to relapse in the marrow with BCMA-negative MM clones. 73 Two other BCMAspecific CAR-T cells are currently being investigated in clinical trials. Preliminary findings were presented at the 2016 ASH meeting by the University of Pennsylvania group. 74 In a phase I dose-escalation study, with second-generation 4-1BB-CD3z antieBCMA-CAR-T cells, 6 patients received split-dose infusions, 10% on day 0, 30% on day 1, and 60% on day 2. Overall, 5 patients developed CRS toxicity; 2 patients required antieIL-6 treatment with tocilizumab. Interestingly, even though these 2 patients had received only 40% of the planned CAR-T cell dose, they achieved a remarkable antitumor response with a stringent CR and a VGPR, respectively. Five months after the last infusion, the patient who achieved VGPR progressed with a concomitant reduction of circulating CAR-T cells. Of note, BCMA expression was lost on MM cells, which is highly suggestive of antigen escape. Overall, the 4 other patients showed stable disease, minimal response, or PD with low expansion of CAR-T cells. Bluebird Bio reported on a cohort of 9 patients with RRMM who were infused with second-generation antieBCMA-CAR-T cells (bb2121) with 4-1BB costimulation. 75 ) after being conditioned with cyclophosphamide and fludarabine. Best responses were achieved after the infusion of 15 Â 10 7 CAR-T cells: 2 patients showed stringent CR and 1 VGPR. CD138 (also known as syndecan 1) is a surface protein expressed on normal and malignant plasma cells, 76 and it binds collagen and fibronectin molecules in the extracellular matrix. Given its high expression on MM cells, it has been considered an attractive target. A Chinese group reported their experience with an anti-CD138 CAR on 5 refractory patients. 77 Multiple infusions were well tolerated and only mild fever was reported; stable disease was achieved in 4 of 5 patients. Nevertheless, these are preliminary findings and further confirmation is awaited. Importantly, CD138 is not specifically expressed by MM cells but it is also expressed by epithelial cells, raising some concerns regarding on-target off-tumor toxicity. Other clinical and preclinical studies with CAR-T cells directed against other MM-specific targets are in progress. A phase I clinical trial of kappa-CD28-CAR-T cells was also conducted at Baylor Hospital. 78 Two other studies with antieCS-1 CAR-T cells 
Immuno-oncologic Approaches in Myeloma
themselves and leading to self-killing of CAR-T cells are another important issue. 79 Other concerns have been raised regarding efficacy, such as depth and duration of antitumor effects, and toxicity profile, such as the potential serious systemic toxicities, including CRS. 80 Moreover, high tumor burdens may be associated with higher risk of CRS. Anecdotal specific toxicities have also been reported. The Pennsylvania group recently published a case report of posterior reversible encephalopathy syndrome after infusion of anti-BCMA CAR-T cells with worsening neurological symptoms despite treatment with tocilizumab and high-dose steroids. However, cyclophosphamide administration reversed the syndrome. 81 
Conclusion
Advances in the understanding of MM biology and its clinical management have recently led to an increased survival rate, reaching up to 8 to 10 years. Several new agents, with different mechanisms of action and different targets, have increased the treatment armamentarium against a complex disease such as MM. These agents include chemotherapeutic agents, immunomodulatory drugs, and proteasome inhibitors, which are currently considered the backbone treatments for MM. Other agents more recently introduced include histone deacetylase inhibitors, the so-called "small molecules," monoclonal antibodies, checkpoint inhibitors, and ACT. Acting on the immune system is an appealing new treatment strategy, whereby checkpoint inhibitors and ACT are the main players. Results on checkpoint blockade in MM are promising, but not yet as good as in solid tumors. One of the reasons could be the impaired immune function that characterizes the immune system of patients with MM. The most promising results have been so far achieved in MM in combination with immunomodulatory drugs, due to the potential synergistic effect on the immune system. Furthermore, checkpoint molecules that are currently clinically exploited are only the tip of the iceberg of the potential checkpoint targets expressed by immune cells. In the near future, data on mAbs targeting lymphocyte activation gene 3 protein, T-cell immunoglobulin domain and mucin domain 3, V-domain immunoglobulin suppressor of T-cell activation, CD47, and other molecules might be available to researchers.
The preliminary clinical success of CAR-T cells in lymphoblastic leukemia has reignited the interest in cell immunotherapy against MM, and this field is now moving forward very rapidly. However, despite durable responses in heavily pretreated patients, results are very preliminary and many open questions remain, including the definition of the best target, a better understanding of toxicities (eg, CRS) and efficacy (depth of response and its duration). Multiple therapies are currently available for MM and many new approaches will probably be available in the near future.
Future and ongoing trials are still necessary to shed light on the role of checkpoint inhibitors and CAR-T cells in a treatment scenario in continuous evolution.
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